Advanced Research on Drugs Against Breast Cancer: From Bench to Bedside
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 313
Special Issue Editor
Special Issue Information
Dear Colleagues,
Breast cancer, a multifaceted disease, remains one of the most prevalent and concerning diseases affecting women worldwide. With its complex nature and significant impact on public health, extensive research efforts are dedicated to understanding, treating, and ultimately eradicating this disease. Breast cancer research encompasses a wide range of scientific disciplines, from molecular biology and genetics to clinical trials and epidemiology. This research is driven by the urgent need to improve early detection methods, develop targeted therapies, and implement effective prevention strategies. With advancements in breast cancer research, our understanding of the disease has been transformed with revolutionized treatment approaches.
The aim of this Special Issue is to bridge the gap between laboratory research (bench) and clinical application (bedside) in the context of drug development for breast cancer. It seeks to highlight the multidisciplinary efforts involved in understanding the molecular mechanisms of breast cancer, identifying novel therapeutic targets, and translating these discoveries into effective treatments for patients. The issue will encompass original research articles, review papers, and perspectives that explore various aspects of breast cancer drug research, from fundamental biology to clinical trials, aiming to foster collaboration and accelerate progress toward improved patient outcomes.
Dr. Lunawati Bennett
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- drug discovery
- therapeutic targets
- preclinical studies
- clinical trials
- molecular mechanism
- biomarkers
- drug resistance
- combination therapies
- translational research
